Founder of The California Peptide Club & President @AGIHouseSF. Exited Founder. Letting you in on the future of longevity
San Francisco, CA
- Tweets 1,174
- Following 374
- Followers 2,301
- Likes 4,440
Pinned Tweet
Edible peptides became a billion-dollar opportunity.
How pharma engineers them to survive your stomach, why a quarter of users quit within a year, and why the answer might be "algae" or "chocolate."
20
13
76
29,074
Lloyd is a killer entrepreneur!
I’m 44.
3x Founder with 6 kids building an AI pharmaceutical company in Texas.
Looking to hire AI-pilled psychos in jobs that aren't normally AI-pilled.
Attorney. Lobbyist. Grant writer. Growth. Ops. PR. CS. EA.
Reply with:
I’m [age]
I do [job]
How AI changed [thing you do]
5
564
This is so timely. Can't wait to visit China this year!
🏮Announcing the Lantern Summit in Shanghai🏮
In 2025, more new medicines launched first in China than anywhere else on Earth.
That has never happened before.
Drug development has two simultaneous accelerators:
• AI is collapsing design (weeks instead of years).
• China is collapsing development (physical iteration speed).
Here is why that matters, and what Western biotech is missing: 🧵
2
5
1,309
Excited to welcome Lloyd on stage at the Peptide Club Austin this Sunday. Link to apply is below.
It's Demo Day!
12 weeks ago, RonanRx was an idea.
Today we’re growing 57% week over week and building a full-stack pharmaceutical company.
Fundraising was the easy part.
Now we have to build the damn thing.
This is where the real story starts.
1
1
2
712
We've run 4 oversubscribed Peptide Club events in San Francisco. Now we're coming to Austin
We're talking about the future of personalized peptide protocols with @larmbrust from @Ronan_RX
& @drelenazinkov on the growth hormone stacks of the future.
Sign-up link below
Made with AI
2
2
7
2,517
First time on KLOW.
KLOW is GHK-Cu (thus the blue color), KPV, and BPC-157 + TB-500 in 5:1:1:1 ratio.
After the Wolverine stack (BLC-157 + TB-500) worked great for me, l’ll report how it changes my skin + gut health over 6 weeks.
49
4
199
22,794
Julius Ritter retweeted
it’s dinner time excited to host a small dinner for founder / researcher friends next tues in sf w @0x_ara and @JuliusYRitter
alr have some pretty cracked post series a founders, researchers in semicon / voice ai and some of our investor friends
comment / dm for invite link! last few spots
3
2
10
457
Just visited a peptide manufacturing site that'll soon make the API in California at reasonable pricing.
The future is so bright
20
1
125
11,578
The most interesting chart from the article: GLP-1 pill sales have stagnated.
Users are reporting GI issues as a problem, but the reason for this is simpler: People haven't heard of GLP.
Massive opportunity to ace distribution around oral peptides.
Edible peptides became a billion-dollar opportunity.
How pharma engineers them to survive your stomach, why a quarter of users quit within a year, and why the answer might be "algae" or "chocolate."
2
2
8
2,254
Got the founders of the GLP-1 chocolate at the house: They can’t share their IP but say they’re using “double-encapsulation” 🤫
Peptide chocolates/gummies are coming.
New delivery mechanisms of peptides, IF EFFECTIVE (and it works for GLP-1s), will crush it on TikTok.
Got early access to chocolate from founder who pivoted from koshla-backed biotech into the peptide CPG-space.
Who’d try?
1
14
2,137
Julius Ritter retweeted
Lots of misinformation I’m seeing on X regarding the peptide meeting today and what the recommendations actually mean.
Today’s PCAC votes (so far favorable for BPC-157 and KPV!) are advisory only.
A “yes” recommendation does not immediately allow compounding. The FDA still has to decide and complete formal rulemaking.
If the agency ultimately adds these peptides to the 503A Bulks List, licensed 503A pharmacies could compound them for patients under a valid prescription, with standard quality and sterility requirements.
Until that process finishes, nothing changes in current compounding restrictions.
The recommendations are a step toward a regulated pathway, not a green light (yet).
JUST IN: FDA advisory panel votes to expand pharmacy access to BPC-157, a peptide promoted for injury recovery and gut healing.
10
10
76
17,844
